Covishield Controversy: India Vaccine Trials Lack Transparency?

At a time when the Serum Institute of India is seeking emergency authorisation of Covishield (which is what the COVID-19 vaccine being developed by Oxford and AstraZeneca is called in India), the company has found itself embroiled in a big controversy over allegations of side effects from trials.

While on one hand, the company CEO Adar Poonawala has dubbed the vaccine to be "highly effective" against coronavirus and already announced plans of manufacturing a million doses by December 2020, a 40-year-old man from Chennai has filed a Rs 5-crore worth lawsuit against the company on 21 November alleging severe neurological impairment in aftermath of the trial shot.

In a legal notice, the volunteer has also asked for the trials and further manufacturing plans to be suspended, failing to do which he warned of more legal action.

The company in turn sued the volunteer back, on 30 November, with a 100 crore rupees worth lawsuit claiming his allegations to be “malicious and misconceived.”

But how did this controversy start and in this mesh of lawsuits and counter lawsuits, what does this development mean for us? In this podcast you'll hear from Bioethics experts Dr Anant Bhan and Dr Amar Jesani talk about their concerns around the Serum Institute controversy. Tune in!

Producer and Host: Shorbori Purkayastha

Editor: Shelly Walia

Music: Big Bang Fuzz

Listen to The Big Story podcast on:

Apple: https://apple.co/2AYdLIl

Saavn: http://bit.ly/2oix78C

Google Podcasts: http://bit.ly/2ntMV7S

Spotify: https://spoti.fi/2IyLAUQ

Deezer: http://bit.ly/2Vrf5Ng